Modes of biochemical failure after primary radiation therapy may identify aggressive sub-types

The most widely used definition of biochemical failure after primary radiation therapy is the so-called “Phoenix” definition. It’s called that because it was adopted by consensus at a meeting of the American Society for Radiation Oncology (ASTRO) in Phoenix, AZ, in 2005. … READ MORE …

Modern 5-year outcome data after radiotherapy for very high-risk patients

A newly published paper reports 5-year outcome data from a series of men initially diagnosed with very high-risk, but localized prostate cancer — all of whom were treated with either dose-escalated external beam radiation therapy (EBRT) or pelvic radiation + permanent interstitial seed implantation (combined modality radiotherapy or CMRT). … READ MORE …

5-year cumulative incidence of complications after surgery or radiation therapy

A new report just published in Lancet Oncology provides data on complications other than incontinence and erectile dysfunction (ED) after surgical or radiotherapeutic treatment of prostate cancer within 5 years of the initial treatment. … READ MORE …

AUA, ASTRO issue new guidance on radiation after radical prostatectomy

So the American Urology Association (AUA) is clearly “on a roll” when it comes to guidance on the detection and management of prostate cancer. This is the third new guidance document issued in a matter of days. … READ MORE …

Salvage ADT after failure of radiation therapy — the art of good timing

The art of good timing and good patient selection is important to the appropriate use of salvage hormone therapy in all men who are in biochemical failure after first- or second-line radiation therapy. A study published in “the Red Journal” helps to make this point. … READ MORE …

PBRT vs. IMRT — are we about to get the definitive trial?

According to an article in the Boston Globe this morning, we are (supposedly and finally) going to get the study needed to try to demonstrate whether there is a real clinical benefit to proton beam radiation therapy as compared to modern, intensity-modulated radiation therapy in men with localized prostate cancer! … READ MORE …

PBRT and prostate cancer: your breakfast read on Bloomberg.com

Ye of faith … and ye of rather less faith … in the merits of proton beam radiation therapy (PBRT) compared to other forms of treatment for management of localized prostate cancer may want to read through Robert Langreth’s article (“Prostate cancer therapy too good to be true explodes health cost“) posted this morning on the Bloomberg.com web site. … READ MORE …

ADT + radiotherapy in the treatment of high-risk prostate cancer; today’s “best practices”

A new review published recently in the British Journal of Cancer addresses appropriate current practice regarding the use of neoadjuvant and adjuvant androgen deprivation therapy (ADT) in combination with radiation therapy in the management of patients with high-risk localized and locally advanced forms of prostate cancer. … READ MORE …

Adjuvant degarelix in combination with radiation therapy (instead of an LHRH agonist + an antiandrogen)

According to an announcement from the European Association for Urology (EAU) earlier today, data from a recently completed trial demonstrate that degarelix is “non-inferior” to the LHRH agonist goserelin acetate + the antiandrogen bicalutamide at reducing prostate volume in men with advanced hormone- dependent prostate cancer. … READ MORE …

First directly comparative data question safety of PBRT vs. IMRT

For the first time, some 15 years after proton beam radiation therapy (PBRT) was initially popularized as a potential treatment for prostate cancer by the group at Loma Linda, we have an independent assessment of the risk for side effects associated with this form of radiation therapy … and the comparative data are not good. … READ MORE …

Self-referral and the role of IMRT in treatment of prostate cancer

The issue of whether some urology practices are investing in equipment capable of delivering intensity-modulated radiation therapy (IMRT) with financial motives is back on the front burner again. … READ MORE …

ASTRO claims “Proton therapy effective prostate cancer treatment”

A media release issued yesterday by ASTRO reads as follows: … READ MORE …

Patient satisfaction after first-line treatment for localized prostate cancer (in Germany)

A new article in the journal Anticancer Research suggests that patients had greater satisfaction after modern forms of external beam radiation therapy (EBRT) than after some other standard forms of first-line treatment. Of course the absolute truth of this conclusion may be affected by the details of the study. … READ MORE …

Re-irradiation of the prostate after first-line radiation therapy for “localized” prostate cancer

The use of second-line radiation therapy following biochemical progression after first-line radiation therapy for localized forms of prostate cancer has long been limited by concerns about tolerance for rectal and related radiation toxicities. … READ MORE …

Acute and mid-term side effects of high-dose, image-guided IMRT in first-line treatment of localized prostate cancer

Two recent papers have reported data relevant to the application of high-dose, image-guided, intensity-modulated forms of radiation therapy (IGRT/IMRT) in the first-line treatment of men with localized prostate cancer. … READ MORE …